top of page



Benevira Announces Positive Preclinical Data for its Novel COVID-19 Treatment. 

NEW YORK - May 24, 2022 - Benevira, a global synthetic biology company focused on treating viral disease, today announced positive preclinical safety and efficacy data on β521, a novel SARS-CoV-2 therapy, demonstrating robust tolerability and efficacy against several SARS-CoV-2 variants. The results showed that β521 was 99% effective in preventing SARS-CoV-2 infections in Vero cells grown in the presence of a high titer of delta or omicron variants. In addition, 100% tolerability was observed for β521 in New Zealand rabbits at a maximum dosing concentration. β521 is the lead candidate in the company’s therapeutics pipeline developed to target functional components of viruses that are unlikely to evolve, thus retaining their efficacy as potential new variants emerge.

News & Media: News
Scientist writes in a vial new variant of covid-19 virus from Brazil detected in Minnesota
News & Media: News
President of the Republic of Cyprus – H.E. Nicos Anastasiades
Benevira Meets Cyprus’ President and Minister of Health

November 3, 2022 - Benevira had the pleasure of attending a dinner at the Presidential Palace in Nicosia, Cyprus.  Our CEO, Patricia Kitchen, had the opportunity to meet with the President of the Republic of Cyprus, H.E. Nicos Anastasiades (top picture) and the Minister of Health, Mr. Michalis Hadjipantela (bottom-right) while continuing discussions of the technology being developed by Benevira for the protection against SARS-CoV-2.

Minister of Health in the Republic of Cyprus – Mr. Michalis Hadjipantela, with Patricia Kitchen
bottom of page